|
| Timing from diagnosis (d) |
Management | Outcomes |
|
| 0 | CT
laboratory | Tumor size: 12.5 × 8.5 cm
AFP: 6173 ng/mL |
| 5 | TACE (gelfoam, an emulsion of 5 mL iodized oil and 40 mg doxorubicin, 1000 mg floxuridine, and 20 mg hydroxycamptothecin) | Angiography: tumor staining; APS |
| 9 | Sorafenib (400 mg twice a day) | Stopped at 354 days after the diagnosis |
| 18 |
Laboratory | AFP: 4179 ng/mL |
| 27 | TACE (gelfoam, an emulsion of 5 mL iodized oil and 40 mg doxorubicin, 1000 mg floxuridine, and 20 mg hydroxycamptothecin) | Angiography: tumor shrink; reestablishment of the APS |
| 59 | CT | Tumor size: 9.6 × 7.1 cm |
| 84 | TAC (20 mg hydroxycamptothecin)
laboratory | Angiography: tumor shrink; reestablishment of the APS;
AFP: 4247 ng/mL |
| 87 | CT | Tumor size: 9.0 × 6.0 |
| 151 | TAC (20 mg hydroxycamptothecin)
laboratory | Angiography: tumor shrink
AFP: 6281 ng/mL |
| 152 | CT | Tumor size: 8.8 × 6.0 cm |
| 209 | TAC (20 mg hydroxycamptothecin) | Angiography: tumor progression |
| 213 | CT | Tumor size: 10.7 × 7.1 cm; tumor metastasis in right hepatic lobe; mild ascites |
| 262 | CT | Tumor size: 10.9 × 7.4 cm; moderate ascites |
| 335 | CT | Tumor size: 14.4 × 8.4 cm; moderate ascites; gastric varices |
| 354 | CT | Tumor size: 14.4 × 8.5 cm; moderate ascites; gastric varices; both left and right hepatic lobes were invaded by the tumor |
| laboratory | AFP: 80442 ng/mL |
| 366 | — | Died from liver function failure |
|
